Development and distribution of medical devices, including TAVI valve systems for the minimally invasive treatment of heart valve diseases

Boston Scientific Corporation

Marlborough, MA (USA) · Ecublens (Switzerland)New on Amplifa

Symetis: 2001Founding of the acquired manufacturer Symetis

435 Mio. USDAcquisition sum of Symetis (2017)

CHF 38,4 Mio.Symetis revenue 2016

55 %Symetis CAGR since 2012

About Boston Scientific

Boston Scientific is a global medical technology company based in Marlborough, Massachusetts, that develops and distributes medical solutions for unmet patient needs. In the area of structural heart diseases, the company offers minimally invasive systems for Transcatheter Aortic Valve Implantation (TAVI), including the ACURATE TA™ and ACURATE neo™/TF™ valve systems, which were added to the portfolio in 2017 through the acquisition of the Swiss manufacturer Symetis SA for 435 million US dollars. These systems are used to treat severe, symptomatic aortic stenosis in patients at high risk for surgical valve replacement; the replacement valve is inserted percutaneously via a catheter system instead of open-heart surgery. The ACURATE systems are distributed in Europe and other markets outside the USA; they are not available in the USA. Boston Scientific trades on the NYSE under the ticker BSX.

Site: Marlborough
Materials: Transcatheter Aortic Valve Systems
Industries: Medical Technology, Interventional Cardiology, Structural Heart Diseases (TAVI)

01
Research and Development
02
Manufacturing
03
Regulation/CE Certification
04
Sales
05
Clinical Follow-up (Registry)

Development and Manufacturing

TAVI

Transcatheter Aortic Valve Systems

ACURATE TA™ and ACURATE neo™/TF™ for the minimally invasive treatment of severe aortic stenosis.

Locations

Marlborough

Corporate Headquarters

Ecublens

Symetis acquisition site (TAVI Systems manufacturing, Switzerland)

Inside the production

Boston Scientific Corporate Headquarters, CEO Mike Mahoney

Industries

Medical TechnologyInterventional CardiologyStructural Heart Diseases (TAVI)

History

2001
Founding of Symetis SA in Switzerland.
2016
Symetis achieves revenue of CHF 38.4 million; growth with CAGR of 55% since 2012.
2017
Boston Scientific announces the acquisition of Symetis SA for 435 million USD in cash on March 30 and completes the acquisition on May 16, 2017; distribution of ACURATE valve systems in Europe and outside the USA begins.